Skip to main content
SpringerLink
Log in

Bunazosin in patients with impaired hepatic or renal function

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

Following a single oral dose of 6 mg bunazosin, a novel α1-adrenoceptor antagonist, the pharmacokinetics and blood pressure behaviour of 37 patients were studied. 12 subjects had normal renal and hepatic function (mean creatinine clearance (GFR) 107±240 ml/min, antipyrine clearance (AP Cl) 47±10.2 ml/min; x±SD), 13 subjects had impaired renal function (mean GFR 38±11.5 ml/min, AP Cl 39±4.0 ml/min), and 12 patients had liver cirrhosis which was confirmed by liver biopsy (mean AP Cl 18±9.2 ml/min, GFR 92±8.1 ml/min). The groups studied were matched for age and body weight. The area under the plasma level time curve (AUC0−∞) of bunazosin increased from 96.6±48.7 μg.ml−1. h in the normals to 157.0±101.0 μg.ml−1.h in the liver patients and to 298.2±199.4 μg.ml−1.h in patients with impaired renal function (P<0.05). As there was a close correlation between plasma levels and antihypertensive activity of bunazosin in the present study, dosage adjustment of the α1-receptor blocker in patients with impaired liver and kidney function appears to be mandatory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baba T., Tomiyama T., Murabayashi S., Takebe K. (1990): Renal effects of bunazosin, a new α1-adrenoceptor blocker, in patients with mild to moderate essential hypertension. J. Cardiovasc. Pharmacol., 15, 826–830.

    Article  CAS  PubMed  Google Scholar 

  2. Kawasaki T., Uezono K., Abe I., et al. (1981): Antihypertensive effect of E-643, a new alpha-adrenergic blocking agent. Eur. J. Clin. Pharmacol., 20, 399–405.

    Article  CAS  PubMed  Google Scholar 

  3. Oishi S., Sasaki M., Ohno M., Umeda T., Sato T. (1988): Periodic fluctuation of blood pressure and its management in a patient with pheochromocytoma. Case report and review of the literature. Jpn Heart J., 29, 389–399.

    CAS  PubMed  Google Scholar 

  4. Hata F., Kondo S., Kagawa K., Ishida H. (1982): Characteristics of (3H)E-643-binding to alpha adrenoceptors. Jpn J. Pharmacol., 32, 181–187.

    Article  CAS  PubMed  Google Scholar 

  5. Shoji T., Daiku Y., Igarashi T. (1980): Alpha-adrenoceptor blocking properties of a new antihypertensive agent, 2-(4-(n-butyryl)-homopiperazine-1-y1)-4-amino-6,7-dimethoxyquinazoline (E-643). Jpn J. Pharmacol., 30, 763–772.

    Article  CAS  PubMed  Google Scholar 

  6. Shoji T. (1981): Comparison of pre- and postsynaptic alpha-adrenoceptor blocking effects of E-643 in the isolated vas deferens of the rat. Jpn J. Pharmacol., 31, 361–368.

    Article  CAS  PubMed  Google Scholar 

  7. Nakano A., Tamura T., Hatori M., Hasegawa A., Susuki T., Murata K. (1989): Exercise testing of the chronic effects of bunazosin hydrochloride on dilated cardiomyopathy. Arnzeimittelforsch., 39, 1590–1592.

    CAS  Google Scholar 

  8. Mescheder A., Halabi A., Kirch W. (1992): Antihypertensive activity, cardiac performance and pharmacokinetics of bunazosin, a novel α1-adrenoceptor antagonist, in patients with normal and impaired renal function. Vth World Conference on Clinical Pharmacology and Therapeutics. 0-13-03 Abstr. 113.

  9. Wagner J.G. (1975): Fundamentals of clinical pharmacokinetics. Hamilton, Illinois, Drug Intelligence Publications, p. 71.

    Google Scholar 

  10. Dylewicz P., Kirch W., Santos S.R., Hutt H.J., Mönig H., Ohnhaus E.E. (1987): Bioavailability and elimination of nitrendipine in liver disease. Eur. J. Clin. Pharmacol., 32, 563–568.

    Article  CAS  PubMed  Google Scholar 

  11. Helger R., Rindfrey H., Hilgenfeldt J. (1974): Eine Methode zur direkten Bestimmung des Kreatinins in Serum und Harn ohne Enteiweißung nach einer modifizierten Jaffé-Methode. Z. Klin. Chem. Klin Biochem., 12, 334–349.

    Google Scholar 

  12. Yamoto C., Takahashi T., Kinoshita K. Fujita T. (1982): The metabolic fate of 4-amino-2-(butanoyl-hexhydro-1H-1, 4-diazepin-1-yl)-6,7-dimethoxy-quinazoline HCl. Xenobiotica, 12, 549–559.

    Article  Google Scholar 

  13. Lameire N., Gordts J. (1986): A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure. Eur. J. Clin. Pharmacol., 31, 333–337.

    Article  CAS  PubMed  Google Scholar 

  14. Carlson R.V., Bailey R.R., Begg E.J., Colishaw M.G., Sharman J.R. (1986): Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin. Pharmacol. Ther., 40, 561–566.

    CAS  PubMed  Google Scholar 

  15. Somberg J.C., Achari R., Laddu A.R. (1991): Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. Am. Heart J., 122, 901–905.

    Article  CAS  PubMed  Google Scholar 

  16. Köhler H., Kirch W., Höffler D. (1974): Pharmakokinetic und Dosierung von Dextran 40 in Abhängigkeit von der Nierenfunktion. Klin. Wochenschr., 52, 1111–1114.

    Article  PubMed  Google Scholar 

  17. Soons P.A., Ankermann T., Breimer D.D., Kirch W. (1992): Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function. Eur. J. Clin. Pharmacol., 42, 423–427.

    Article  CAS  PubMed  Google Scholar 

  18. Soons P.A., Breimer D.D. (1992): Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. Br. J. Clin. Pharmacol., 32, 11–16.

    Google Scholar 

  19. Lowenthal D.T., Hobbs D., Affrine M.B., Twomey T.M., Martinez E.W., Onesti G. (1980): Prazosin kinetics and effectiveness in renal failure. Clin. Pharmacol. Ther., 27, 779–783.

    CAS  PubMed  Google Scholar 

  20. Rubin P., Jackson G., Blaschke T. (1980): Studies on the clinical pharmacology of prazosin. II: The influence of indomethacin and of propranolol on the action and disposition of prazosin. Br. J. Clin. Pharmacol., 10, 33–39.

    CAS  PubMed  Google Scholar 

  21. Ahmed J.H., Elliot H.C., Grant A.C., Rodger R.S.C., Reid J.L. (1990): The pharmacokinetics and pharmacodynamics of nicardipine in patients with renal impairment. Br. J. Clin. Pharmacol. 29, 145–146.

    Google Scholar 

  22. Ankermann T., Osterkamp U., Santos S.R., Kirch W. (1989): Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. Eur. J. Clin. Pharmacol., 36, 433–437.

    Article  CAS  PubMed  Google Scholar 

  23. Kirch W., Hutt H.J., Heidemann H., Rämsch K., Janisch H.D., Ohnhaus E.E. (1984): Drug interactions with nitrendipine. J. Cardiovasc. Pharmacol., 6, S982-S985.

    Article  CAS  PubMed  Google Scholar 

  24. Kirch W., Rämsch K.D., Dührsen U., Ohnhaus E.E. (1984): Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int. J. Clin. Pharmacol. Res., 3, 381–384.

    Google Scholar 

  25. Lowenthal D.T., Briggs W.A., Gibson T.P., Nelson H., Cirkensas J. (1976): Pharmacokinetics of oral propranolol in chronic renal disease. Clin. Pharmacol. Ther., 16, 761–769.

    Google Scholar 

  26. Jungers P., Ganeval D., Pertuiset N., Chaveau P. (1986): Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. Am. J. Med., 80 (Suppl. 5B), 94–99.

    Article  CAS  PubMed  Google Scholar 

  27. Kleinbloesem C.H., Van Harten J., Wilson J.P.H., et al. (1986): Nifedipine. Kinetics and hemodynamic effects in patients with liver cirrhosis after i.v. and oral administration. Clin. Pharmacol. Ther., 40, 21–28.

    CAS  PubMed  Google Scholar 

  28. Dylewicz P., Kirch W., Santos S.R., et al. (1987): Bioavailability and elimination of nitrendipine in liver disease. Eur. J. Clin. Pharmacol., 32, 563–568.

    Article  CAS  PubMed  Google Scholar 

  29. Cruickshank J.M. (1980): The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am. Heart J., 100, 160.

    Article  CAS  PubMed  Google Scholar 

  30. Halabi A., Endell W., Halabi I., Kirch W. (1990): Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension. J. Cardiovasc. Pharmacol., 16, 81–86.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I. Medizinische Klinik, Christian-Albrechts-Universität Kiel, Schittenhelmstr. 12, 2300, Kiel 1, Germany

    A. Halabi, A. Nokhodian & W. Kirch

Authors
  1. A. Halabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Nokhodian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Kirch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halabi, A., Nokhodian, A. & Kirch, W. Bunazosin in patients with impaired hepatic or renal function. Eur. J. Drug Metab. Pharmacokinet. 18, 309–313 (1993). https://doi.org/10.1007/BF03188813

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03188813

Keywords

Search

Navigation